GlassScriptPhysician profile
Craig Joseph Brown
NPI 1891038535
$425.23
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $81.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $100.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.96 | 2019-2020 | |
| Amgen INC. | $37.96 | 2019 | |
| Pfizer INC. | $28.52 | 2019-2020 | |
| Novo Nordisk INC | $27.92 | 2019 | |
| Genentech USA, INC. | $23.97 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.40 | 2019 | |
| Glaxosmithkline, LLC. | $19.04 | 2020 | |
| Merck Sharp & Dohme LLC | $12.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2019 | |
| Lilly USA, LLC | $11.54 | 2019 | |
| Shire North American Group INC | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.